10-Q: Sangamo Therapeutics Faces Delisting, Seeks Funding Amidst Financial Woes

Sangamo Therapeutics reports significant financial challenges, including a Nasdaq delisting and substantial doubt about its ability to continue as a going concern, while advancing its neurology pipeline.

Summary

• Sangamo Therapeutics is facing severe financial difficulties, including a delisting from the Nasdaq Capital Market and a transition to trading on the OTCQB Venture Market.
• The company has substantial doubt about its ability to continue as a going concern, with cash reserves estimated to last only into the third quarter of 2026.
• Significant cost-cutting measures, including potential workforce reductions, are being considered to preserve cash.
• The company is actively seeking substantial additional capital through strategic collaborations, equity, or debt financing.
• Despite financial challenges, Sangamo is advancing its neurology-focused pipeline, including the Fabry disease program (isaralgagene civaparvovec) and preclinical programs for small fiber neuropathy and prion disease.
• The Fabry disease program is progressing towards a Biologics License Application (BLA) submission for accelerated approval, with data showing potential for durable clinical benefits.
• The company has secured significant upfront payments and is eligible for substantial future milestones and royalties from collaborations with Eli Lilly, Astellas, Genentech, and previously Pfizer and Alexion.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a very negative filing due to the Nasdaq delisting, substantial going concern doubt, and critical need for immediate funding, overshadowing pipeline progress.

Positives

• Clinical data for isaralgagene civaparvovec (ST-920) in Fabry disease shows potential for a one-time, durable treatment with meaningful clinical benefits, including improved renal function and stable cardiac function.
• The Fabry disease program has a clear pathway to accelerated approval from the FDA, with two-year eGFR data potentially serving as confirmatory evidence for traditional approval.
• A rolling BLA submission for isaralgagene civaparvovec is in progress, with preclinical and clinical modules submitted to the FDA.
• The antibody assay companion diagnostic for isaralgagene civaparvovec has been accepted by the FDA's CDRH for Premarket Approval (PMA).
• Productive interactions with regulatory agencies (MHRA for ST-506) and progress in preclinical programs (ST-503, ST-506) are noted.
• The company has secured significant upfront payments and is eligible for substantial future milestone and royalty payments from its collaborations.
• The company has $27.6 million in cash and cash equivalents as of March 31, 2026, and approximately $129.5 million available under its at-the-market offering program.

Negatives

• The company received a delisting determination from Nasdaq due to failure to meet the minimum bid price requirement, and its stock now trades on the OTCQB Venture Market.
• There is substantial doubt about the company's ability to continue as a going concern, with cash reserves projected to last only into the third quarter of 2026.
• The company will likely need to significantly scale back operations or pursue strategic alternatives, including potential liquidation or bankruptcy protection, if substantial funding is not secured.
• Revenues decreased by 77.6% to $1.4 million for the three months ended March 31, 2026, compared to $6.4 million in the prior year period, primarily due to the recognition of revenue from Pfizer in the prior year.
• Operating expenses were $33.4 million for the three months ended March 31, 2026, a slight decrease from $36.1 million in the prior year, but R&D expenses increased slightly.
• General and administrative expenses decreased by 32% due to lower personnel costs and professional services, reflecting cost-cutting measures.
• The company has been unable to secure a commercialization partner for its Fabry disease program despite extensive efforts.
• Future financing is highly uncertain and dependent on securing substantial upfront funding from partnerships or other transactions.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, requiring substantial additional financing in the very near term.
• Failure to secure adequate funds could lead to ceasing operations entirely, liquidating assets, or seeking bankruptcy protection.
• The delisting from Nasdaq and trading on the OTCQB Venture Market may adversely affect stock liquidity and the ability to raise capital.
• The company has no approved products and its success depends on the results of preclinical studies and clinical trials, which are expensive, lengthy, and unpredictable.
• Core preclinical neurology programs are in early stages, and there's a risk of encountering difficulties in advancing them.
• Success in early trials may not be indicative of later trial results.
• The company has historically incurred significant operating losses and anticipates continued losses.
• Disruptions at the FDA could negatively impact the development and approval of product candidates.
• The biotechnology sector is highly competitive, and competitors may develop superior or faster-to-market technologies.
• Manufacturing, storage, and transport of product candidates are complex, expensive, and risky.
• Even with successful development and regulatory approval, products may not gain market acceptance.
• Protecting intellectual property is challenging and costly, and there's a risk of infringing on others' intellectual property.
• The company may face patent or intellectual property lawsuits.
• Difficulties in hiring, integrating, and retaining qualified employees may persist.
• Unfavorable global economic conditions could negatively impact operations and the ability to continue as a going concern.
• Stock price volatility could lead to substantial losses for investors and potential litigation.
• Significant impairment of long-lived assets has occurred and may continue.

Future Outlook

The company's future outlook is heavily dependent on securing substantial additional funding, which is uncertain. Without it, operations may need to be significantly scaled back, potentially leading to liquidation or bankruptcy. Despite these financial challenges, the company plans to continue advancing its neurology pipeline, particularly the Fabry disease program towards BLA submission, subject to funding availability. Research and development expenses are expected to increase in the near-term for BLA readiness activities and advancement of other programs, contingent on securing adequate funding.

Management Comments

• Management believes that substantial doubt exists about the company's ability to continue as a going concern for at least the next 12 months.
• The company's ability to continue to operate as a going concern is dependent upon its ability to raise substantial additional capital to fund its operations and support its research and development endeavors.
• If adequate funds are not available in the very near term, the company will be required to take significant additional actions to address liquidity needs, including substantial cost reduction measures and potentially ceasing operations entirely or seeking bankruptcy protection.
• The perception of the company's ability to continue to operate as a going concern has made and will continue to make it more difficult to obtain financing.
• The company is actively considering a variety of additional significant cost-cutting measures designed to preserve cash resources and the value of assets, including further reductions in its workforce.

Industry Context

StockSavvy.ai notes that Sangamo Therapeutics' situation highlights the extreme financial pressures faced by many early-stage biotechnology companies, particularly those without approved products and relying heavily on external funding and partnerships. The Nasdaq delisting and going concern warnings underscore the high-risk, high-reward nature of the sector, where scientific progress must be balanced with robust financial management and successful capital raising.

Comparison to Industry Standards

• The revenue decline of 77.6% for the quarter is significant, even for a development-stage biotech, and contrasts with companies that have established revenue streams from approved products.
• The substantial doubt about going concern is a critical indicator, shared by many pre-revenue or early-revenue biotechs, but Sangamo's cash runway into Q3 2026 is shorter than many peers who might have 12-18 months of runway.
• The progression of the Fabry disease program towards BLA submission aligns with industry standards for advancing gene therapies, but the company's ability to fund this critical phase is a major concern compared to well-capitalized competitors.
• The reliance on collaborations for funding is standard in the industry, but Sangamo's difficulty in securing a commercialization partner for its Fabry program is a significant hurdle, unlike companies with multiple active partnerships or marketed products.

Legal Proceedings

• The company is not party to any material pending legal proceedings.

Stakeholder Impact

• Shareholders face significant risk of dilution from future equity offerings and potential loss of investment if the company cannot secure funding or is forced into bankruptcy.
• Employees may face job reductions or uncertainty due to cost-cutting measures and the going concern issues.
• Creditors and suppliers may face payment delays or defaults if the company's financial situation deteriorates.
• Collaborators and partners may be impacted by the company's financial instability and potential operational scaling back.

Next Steps

• Continue business development discussions for a potential Fabry commercialization agreement.
• Complete the rolling BLA submission for isaralgagene civaparvovec as early as the summer of 2026, subject to funding.
• Continue preclinical development for ST-503 (small fiber neuropathy) and ST-506 (prion disease).
• Pursue additional strategic collaborations and financing options to address liquidity needs.
• Attend the Nasdaq Hearings Panel on June 9, 2026, to appeal the delisting determination.

Key Dates

Recommendation

The severe financial distress, including Nasdaq delisting and substantial doubt about going concern, coupled with the critical need for immediate funding and the difficulty in securing partnerships, presents an extremely high-risk profile. While pipeline progress exists, the immediate existential financial threats outweigh the potential future value, making it a sell recommendation.

Keywords

Sangamo Therapeutics, SEC Filing, 10-Q, Genomic Medicine, Gene Therapy, Neurology, Fabry Disease, Isaralgagene Civaparvovec, Nasdaq Delisting, Going Concern, Biologics License Application, Clinical Trials, Collaboration Agreements, Biotechnology